Hologic Inc
NASDAQ:HOLX
Hologic Inc
EPS (Diluted)
Hologic Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hologic Inc
NASDAQ:HOLX
|
EPS (Diluted)
$3
|
CAGR 3-Years
-22%
|
CAGR 5-Years
59%
|
CAGR 10-Years
33%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
EPS (Diluted)
$6
|
CAGR 3-Years
1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
0%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
EPS (Diluted)
$1
|
CAGR 3-Years
22%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
EPS (Diluted)
$7
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
19%
|
|
|
Abbott Laboratories
NYSE:ABT
|
EPS (Diluted)
$7
|
CAGR 3-Years
25%
|
CAGR 5-Years
30%
|
CAGR 10-Years
18%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
EPS (Diluted)
$6
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
18%
|
|
Hologic Inc
Glance View
Hologic Inc., headquartered in Marlborough, Massachusetts, crafts a narrative deeply intertwined with the vital mission of women's health. Established in 1985, the company has grown into a prominent player in the medical device and diagnostics realm. Hologic’s success is anchored in its core business sectors: Breast & Skeletal Health, Diagnostic Solutions, GYN Surgical, and Medical Aesthetics. The cornerstone of this expansive operation is innovation, driving the development of advanced technologies like 3D mammography systems that revolutionize breast cancer detection. This strategic focus on high-value diagnostics and medical equipment allows Hologic to capture significant market share, ensuring a steady revenue stream from both capital equipment sales and ongoing service and maintenance contracts. Beyond its robust presence in imaging and diagnostics, Hologic amplifies its influence through a comprehensive array of solutions for early stage disease detection and treatment. Their Diagnostic Solutions arm, particularly strengthened by molecular diagnostic tests, is a response to the increasing global demand for rapid and accurate testing solutions—a need only intensified by recent global health challenges. These products not only provide critical tools for healthcare professionals but also secure recurring income for Hologic through the sale of consumables and tests. By embedding itself in the cycles of medical advancements and enhancing the standard of care, Hologic generates sustainable growth and remains a crucial ally in both public and specialized health sectors. The company’s blend of technology-driven products and strategic agility enables it to navigate dynamic markets while maintaining a resolute focus on improving health outcomes around the world.
See Also
What is Hologic Inc's EPS (Diluted)?
EPS (Diluted)
3.2
USD
Based on the financial report for Dec 28, 2024, Hologic Inc's EPS (Diluted) amounts to 3.2 USD.
What is Hologic Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
33%
Over the last year, the EPS (Diluted) growth was 50%. The average annual EPS (Diluted) growth rates for Hologic Inc have been -22% over the past three years , 59% over the past five years , and 33% over the past ten years .
You don't have any saved screeners yet